Physician profile
Greg D Denenberg
NPI 1235185299
$22,829.25
in general payments reported to CMS, 2019-2025
76 companies · $3,028 in 2025
The $3,028 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,131 · 2020: $2,707 · 2021: $3,875 · 2022: $3,424 · 2023: $3,160 · 2024: $3,505 · 2025: $3,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,660 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,660.16 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,085.44 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $2,564.13 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Pfizer INC. | $2,372.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,074.58 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,507.08 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $1,235.55 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $807.26 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $721.96 | 2020-2025 | Spravato, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $587.71 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $524.06 | 2019-2025 | Jardiance, Ofev, Stiolto Respimat |
| Glaxosmithkline, LLC. | $512.57 | 2020-2025 | Shingrix, Arexvy |
| Mylan Specialty L.P. | $488.00 | 2021-2024 | Yupelri |
| Allergan, INC. | $437.24 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $391.47 | 2019-2023 | Trintellix |
| Esperion Therapeutics, INC. | $335.28 | 2020-2025 | Nexletol |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Denenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.